All In Biotech

Drug Trial Radar · NCT05536141

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

512

Planned (sponsor's estimate)

Start

Oct 26, 2022

Primary completion

Mar 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Summit Therapeutics; AVEO Pharmaceuticals, Inc.
First posted
Sep 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Solid Tumors

Interventions

  • CasdatifanDrug

    Administered as specified in the treatment arm

  • CabozantinibDrug

    Administered as specified in the treatment arm

  • ZimberelimabDrug

    Administered as specified in the treatment arm

  • IpilimumabDrug

    Administered as specified in the treatment arm

  • TivozanibDrug

    Administered as specified in the treatment arm

  • IvonescimabDrug

    Administered as specified in the treatment arm

  • AxitinibDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 4 months
  2. Number of participants with adverse events (AEs)Time frame: Up to 4 months

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    Santa Monica, California · Recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    New Orleans, Louisiana · Recruiting

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    San Antonio, Texas · Recruiting

  • Research Site

    Camperdown, Australia · Not yet recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Sydney, Australia · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.